For CAR-T therapy to make breakthroughs in solid tumors, many problems need to be solved. Among them, how to solve the problem of CAR-T entering the dense solid tumors is the most critical problem. By targeting new targets and continuing to track, many CAR-T clinical trials for the treatment of solid tumors have started in China, and it is expected to achieve breakthroughs in the treatment of solid tumors with CAR-T therapy.
Domestic R&D teams have not only set an example for the internationalization of China’s new drug creation, but also provided better therapeutic effects of tumor chimeric antigen receptor T cell (CAR-T) therapy.
Recently, the CAR-T product cilta-cel, a CAR-T product jointly developed by Nanjing Legend Bio and Johnson & Johnson, has been approved by the U.S. Food and Drug Administration (FDA). In terms of solid tumor treatment,CAR-T product CT041 for solid tumors (stomach cancer) from CARsgen a Chinese Pharma company was the first in the world to obtain clinical trial approvals from the FDA, the State Food and Drug Administration of China, and Health Canada. The confirmatory phase II clinical trial of CT041(Claudin18.2) in China completed with the first patient enrollment in Beijing Cancer Hospital. (Science and Technology Daily reporter Zhang Jiaxing)